Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.
Cureus · 2025
Last updated 2026-06-24| Journal | Cureus, 2025 |
|---|---|
| Citations | 2 |
| Molecules | tirzepatide |
Abstract
Tirzepatide has become a treatment option for weight management, with increasing interest in its effects on skeletal muscle. This systematic review evaluated the impact of tirzepatide on skeletal muscle mass and lean body composition in adults. A structured search of four major databases was conducted up to June 26, 2025, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The included studies were randomized clinical trials that assessed skeletal muscle or lean mass using validated imaging methods in adults treated with tirzepatide. The available evidence suggests that treatment is associated with reductions in fat mass while maintaining the relative preservation of lean mass. Indicators of muscle composition remained stable or showed signs of improvement. These findings support the potential of tirzepatide to improve overall body composition without significantly compromising skeletal muscle. Further research is needed to confirm these results and explore their functional significance over time.
Verbatim abstract via PubMed 40895971 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.